www.idosr.org
©IDOSR PUBLICATIONS

Bwambale, 2025
ISSN: 2579-0781

International Digital Organization for Scientific Research
IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 145-152, 2025.
https://doi.org/10.59298/IDOSR/JES/112.145152

IDOSRJES11200000

Role of Nanodiagnostics in Early Cancer Detection: Advances in Biosensors and Imaging Technologies

Bwambale Isaac

Biomedical Department Kampala International University Uganda
Email: isaac.bwambale@studwc.kiu.ac.ug

ABSTRACT

Early detection of cancer significantly improves therapeutic outcomes, enhances patient survival rates, and reduces treatment costs. However, conventional diagnostic tools often lack the sensitivity and specificity required to detect tumors at their incipient stages. Nanodiagnostics an emerging field at the intersection of nanotechnology and medical diagnostics offers a transformative approach for early cancer detection by utilizing nanoscale materials and devices to enhance diagnostic precision. This review explores recent advances in nanodiagnostic platforms, focusing on biosensors and imaging technologies that leverage unique physicochemical properties of nanoparticles. We highlight various nanomaterials such as gold nanoparticles, quantum dots, magnetic nanoparticles, and carbon-based nanostructures that are engineered into highly sensitive biosensors capable of detecting cancer biomarkers at ultra-low concentrations. Additionally, we examine the integration of nanotechnology in imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging, where nanoparticle contrast agents significantly enhance image resolution and tumor targeting. The review also discusses current clinical challenges, regulatory considerations, and future perspectives for the translation of nanodiagnostics into routine cancer screening. Ultimately, nanodiagnostics holds tremendous potential to revolutionize oncology by enabling non-invasive, highly accurate, and early detection of malignancies.

Keywords: Nanodiagnostics, Early Cancer Detection, Biosensors, Imaging Technologies, Nanoparticles

INTRODUCTION

Cancer remains one of the most formidable challenges in global health, ranking among the leading causes of morbidity and mortality worldwide[1–3]. According to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths in 2020 alone, and this number is projected to increase substantially due to aging populations, lifestyle changes, and environmental factors. The increasing global burden underscores the urgent need for effective strategies not only for treatment but importantly for early detection and diagnosis[3–5].

Early diagnosis is pivotal in improving cancer prognosis. For many cancers, such as pancreatic, ovarian, and lung carcinomas, early-stage detection significantly enhances the chances of successful intervention and long-term survival. Unfortunately, a major challenge in oncology is that many cancers remain asymptomatic during their initial stages or present with nonspecific symptoms. This often results in diagnosis occurring only after the disease has progressed to an advanced or metastatic stage, where treatment options become limited, more invasive, and less effective[6, 7]. Late diagnosis not only compromises patient survival rates but also escalates healthcare costs and impacts quality of life. Current diagnostic modalities for cancer include a combination of blood-based biomarkers, imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound, and tissue biopsies followed by histopathological examination[8, 9]. While these approaches have become standard practice, they still suffer from several drawbacks. For instance, traditional biomarkers often lack specificity and sensitivity, leading to false positives or negatives. Imaging techniques, while powerful, may not detect tumors smaller than a few millimeters or distinguish malignant from benign lesions reliably[8]. Biopsies are invasive, sometimes risky, and often limited by sampling errors due to tumor heterogeneity. Furthermore, these diagnostic procedures can be expensive and resource-intensive, restricting accessibility, especially in low- and middle-income countries[10].

In this context, nanotechnology has emerged as a transformative approach in cancer diagnostics, promising to overcome many limitations of conventional methods. Nanodiagnostics refers to the application of nanoscale materials and devices to detect cancer-related biomarkers or pathological changes at the molecular and cellular levels with enhanced precision[11]. Due to their ultrafine size, nanoparticles can interact intimately with biological molecules, cells, and tissues, enabling the detection of subtle biochemical alterations indicative of early tumorigenesis that might be invisible to traditional techniques. Nanodiagnostic tools leverage unique physical and chemical properties of nanomaterials — such as high surface area-to-volume ratios, optical and magnetic behaviors, and electrical conductivity — to amplify detection signals, improve specificity, and allow multiplexed assays[12]. This capability opens up possibilities for earlier detection of cancers through minimally invasive or even non-invasive means, such as liquid biopsies analyzing circulating tumor DNA (ctDNA), microRNAs (miRNAs), or tumor-derived exosomes in bodily fluids.

Moreover, advances in nanotechnology have facilitated the development of integrated diagnostic platforms that combine biosensors with advanced imaging modalities[13]. These hybrid systems not only improve diagnostic accuracy but can also guide targeted therapies and monitor treatment response in real-time, aligning with the goals of personalized medicine[14]. This review aims to provide a comprehensive overview of the recent advances in nanodiagnostic biosensors and imaging technologies, highlighting their contributions to enhancing early cancer detection. It will explore key types of nanomaterials and their functionalization strategies for specific cancer marker targeting. Additionally, challenges related to clinical translation, regulatory approval, and large-scale manufacturing will be discussed. The review will conclude by offering insights into future perspectives, including the integration of nanodiagnostics with artificial intelligence and point-of-care testing, which hold the potential to revolutionize cancer management worldwide.

2. Nanotechnology in Cancer Diagnostics: An Overview

Nanotechnology refers to the design, manipulation, and application of materials and devices at the nanometer scale, typically between 1 and 100 nanometers (nm). At this scale, materials exhibit unique physical, chemical, and biological properties that are markedly different from their bulk counterparts[15]. These nanoscale properties include enhanced surface reactivity, quantum effects, tunable optical absorption and emission, and increased biocompatibility, making nanomaterials highly suitable for use in biomedical applications, particularly in cancer diagnostics[16]. In the realm of cancer diagnostics, nanotechnology harnesses these special characteristics to improve the sensitivity, specificity, and speed of detecting cancer biomarkers molecules such as proteins, nucleic acids, and metabolites associated with malignancy. Nanoparticles can be engineered to bind selectively to tumor-specific markers through surface functionalization with antibodies, aptamers, peptides, or other targeting ligands[17, 18]. This targeted binding enables highly selective recognition of cancer cells or molecular signatures even at very low concentrations, which is critical for early detection.

One of the most prominent advantages of nanomaterials in diagnostics is their ability to enhance signal transduction. For example, gold nanoparticles exhibit localized surface plasmon resonance, which can be exploited to amplify optical signals in colorimetric or fluorescence-based assays. Magnetic nanoparticles can improve contrast in magnetic resonance imaging (MRI), allowing for more precise tumor localization[19]. Carbon nanotubes and quantum dots provide excellent electrical conductivity and fluorescent properties, respectively, which can be harnessed in biosensors to generate measurable electronic or optical signals upon target binding[20–22].

Key classes of nanomaterials commonly used in cancer diagnostics include:

Gold nanoparticles (AuNPs): Known for their ease of synthesis, biocompatibility, and tunable optical properties, AuNPs serve as contrast agents and signal enhancers in biosensors and imaging.

Magnetic nanoparticles (e.g., iron oxide): These particles improve MRI contrast and enable magnetic separation techniques for isolating circulating tumor cells or biomarkers.

Silica nanoparticles: They provide a stable and biocompatible matrix for loading fluorescent dyes or drugs, facilitating multimodal imaging and targeted delivery.

Liposomes and polymeric nanoparticles: These are used as carriers for diagnostic agents and can be engineered for controlled release and target-specific accumulation.

Dendrimers: Highly branched polymers with modifiable surfaces, ideal for multivalent ligand attachment to enhance binding affinity.

Carbon nanotubes and graphene: Their exceptional electrical and optical properties enable the fabrication of highly sensitive biosensors for detecting nucleic acids and proteins.

In addition to improving traditional diagnostic modalities, nanotechnology has enabled the development of theranostic platforms that combine diagnostic and therapeutic functionalities within a single nanoparticle system[23]. These theranostic agents can simultaneously detect cancer cells and deliver targeted therapy, enabling real-time monitoring of treatment efficacy. Furthermore, nanotechnology supports the miniaturization and integration of diagnostic devices into portable point-of-care platforms, facilitating rapid cancer screening in clinical and even resource-limited settings. Such advances hold promise for decentralized diagnostics, which can significantly impact early detection rates and patient outcomes[24]. However, despite these advantages, challenges remain in translating nanodiagnostic technologies from bench to bedside. Issues related to nanoparticle stability, reproducibility, potential toxicity, regulatory hurdles, and cost-effectiveness need to be addressed for widespread clinical adoption[24].

Overall, nanotechnology represents a powerful and versatile toolkit that is reshaping the landscape of cancer diagnostics. By leveraging the distinctive properties of nanoscale materials, researchers and clinicians can achieve unprecedented sensitivity and specificity, paving the way for earlier detection, better prognostication, and personalized management of cancer.

3. Nanobiosensors for Early Cancer Biomarker Detection

Biosensors are analytical devices that convert biological responses into measurable signals. In nanodiagnostics, biosensors are enhanced using nanomaterials that amplify signal output, increase sensitivity, and enable miniaturization.

3.1 Types of Nanobiosensors

Nanobiosensors represent a cutting-edge fusion of nanotechnology and biotechnology designed to detect specific biological molecules with exceptional sensitivity and precision. Their development has been pivotal in advancing cancer diagnostics by enabling the detection of tumor biomarkers at extremely low concentrations, often far beyond the reach of conventional methods[25, 26]. Among the diverse types of nanobiosensors, electrochemical biosensors have emerged as a widely used platform. These sensors employ nanostructured electrodes, which increase the effective surface area and enhance electron transfer kinetics, thereby improving the detection limits and enabling real-time monitoring of biomarkers such as prostate-specific antigen (PSA) and carcinoembryonic antigen (CEA)[27]. The miniaturization of electrodes at the nanoscale also facilitates integration into portable devices, making them suitable for point-of-care diagnostics.

Optical biosensors constitute another prominent category of nanobiosensors. They exploit the unique optical properties of nanomaterials such as gold nanoparticles and quantum dots. For example, gold nanoparticles exhibit localized surface plasmon resonance (LSPR), a phenomenon where conduction electrons resonate with incident light, producing intense absorption and scattering signals[28]. This effect is highly sensitive to the binding of biomolecules on the nanoparticle surface, enabling detection through colorimetric shifts or enhanced fluorescence. Quantum dots, semiconductor nanocrystals with size-tunable fluorescence, offer advantages like high photostability and broad excitation profiles, making them ideal for multiplexed detection and imaging of cancer-related markers[29]. Piezoelectric and mass-sensitive biosensors utilize nanoscale cantilevers or membranes that respond to biomolecular interactions through changes in mass or mechanical vibrations. When a target biomarker binds to a receptor immobilized on the nanocantilever, the change in mass alters the resonance frequency or deflection of the cantilever, providing a label-free, highly sensitive detection mechanism[30, 31]. These sensors excel in detecting low-abundance cancer biomarkers, offering real-time analysis without the need for complex labeling or amplification steps.

Together, these nanobiosensors provide a diverse toolkit with complementary detection mechanisms suitable for a wide range of cancer diagnostic applications. Their ability to detect molecular changes at very early stages of tumorigenesis positions them as crucial tools in the pursuit of improved clinical outcomes through earlier, more accurate cancer detection.

3.2 Advantages and Applications

Nanobiosensors offer several significant advantages that make them powerful tools in the field of cancer diagnostics. One of the foremost benefits is their rapid detection capability, allowing healthcare professionals to obtain results within minutes or hours rather than days[32]. This speed is crucial for timely clinical decision-making and early intervention, which often directly correlates with improved patient survival. The exceptional specificity and sensitivity of nanobiosensors arise from the high surface-to-volume ratio of nanomaterials, which facilitates efficient binding interactions with target molecules, and the amplification of detection signals through unique physicochemical properties. This results in detection limits reaching femtomolar or attomolar concentrations, enabling the identification of cancer biomarkers at trace levels in blood, saliva, or other biological fluids[33].

Another key advantage is the multiplexing capability of many nanobiosensor platforms, which allows simultaneous detection of multiple biomarkers in a single assay. Cancer is a highly heterogeneous disease, and profiling several markers concurrently provides a more comprehensive molecular signature that can improve diagnostic accuracy and prognostication[34]. Moreover, many nanobiosensors can be integrated into portable, user-friendly devices suitable for point-of-care testing. This accessibility has the potential to decentralize cancer diagnostics, making early detection feasible even in resource-limited settings where access to advanced laboratory facilities is restricted[4, 35, 36]. Several applications illustrate the practical impact of nanobiosensors in cancer detection. For instance, gold nanoparticle-based colorimetric assays have been developed to detect microRNA-21 (miRNA-21), a biomarker commonly overexpressed in breast cancer[27, 33]. The assay produces a visible color change in the presence of the target miRNA, enabling rapid, visual screening without sophisticated equipment. Similarly, carbon nanotube-based field-effect transistors have been engineered to detect mutations in the p53 gene, a critical tumor suppressor frequently altered in many cancers. These devices convert the binding of mutated DNA sequences into measurable electrical signals with high sensitivity and specificity.

By combining speed, sensitivity, multiplexing, and portability, nanobiosensors are transforming cancer diagnostics and paving the way for earlier detection and personalized treatment strategies, ultimately aiming to improve patient outcomes globally.

4. Nanotechnology-Enhanced Imaging Modalities

Imaging techniques are fundamental to cancer diagnosis, staging, and treatment monitoring. They provide non-invasive means to visualize tumors, assess their progression, and evaluate therapeutic responses. Nanotechnology has significantly enhanced traditional imaging modalities by introducing nanoscale contrast agents and probes that improve image quality, specificity, and functional information[37-42]. These nanoparticles can be engineered to selectively target tumor cells or their microenvironment, enabling precise visualization of cancerous tissues even at very early stages or when tumors are small and difficult to detect[43-46].

Magnetic resonance imaging (MRI) is one of the most widely used imaging techniques in oncology. Nanoparticles such as superparamagnetic iron oxide nanoparticles (SPIONs) and gadolinium-based nanomaterials serve as contrast agents to enhance MRI signals[39]. SPIONs generate strong magnetic responses that improve T2-weighted imaging contrast, while gadolinium-based agents enhance T1 contrast. By conjugating these nanoparticles with targeting ligands such as antibodies or peptides, they accumulate preferentially in tumor tissues, improving the sensitivity and specificity of tumor detection. MRI enhanced with these nanoparticles is particularly useful for imaging tumors in organs such as the brain, liver, and lymph nodes, where anatomical detail is critical for diagnosis and treatment planning[47-49].

Optical imaging technologies benefit from nanomaterials like quantum dots and upconversion nanoparticles (UCNPs). Quantum dots are semiconductor nanocrystals with size-tunable fluorescence emission and superior photostability compared to traditional dyes. UCNPs absorb near-infrared light and emit visible light, allowing deeper tissue penetration and reduced background autofluorescence[50-54]. These properties make them invaluable for near-infrared fluorescence imaging, which can be used intraoperatively to precisely delineate tumor margins or track tumor progression in real time. Such imaging enhances surgical outcomes by ensuring complete tumor removal while sparing healthy tissue[55-59].

Nuclear imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) also benefit from nanotechnology. Nanoparticles labeled with radioisotopes can be designed to target tumors and micrometastases with high specificity, providing detailed three-dimensional functional images[60-61]. These images assist in early detection, accurate staging, and evaluation of treatment efficacy. The enhanced tumor uptake and retention of nanoparticle-based agents improve signal-to-noise ratios, making it easier to identify small or otherwise elusive cancer lesions[42]. Computed tomography (CT) imaging is traditionally limited by the biocompatibility and specificity of iodine-based contrast agents. Nanoparticles composed of gold or bismuth offer promising alternatives due to their higher atomic numbers, which provide stronger X-ray attenuation and thus better contrast enhancement. Moreover, these nanoparticles can be functionalized to target tumors selectively, reducing nonspecific distribution and potential side effects. This improves tumor visualization and may aid in earlier diagnosis and more precise tumor characterization[43].

Overall, nanotechnology-enhanced imaging modalities are revolutionizing cancer diagnostics by providing higher resolution, better specificity, and multifunctional capabilities that integrate diagnosis with therapeutic monitoring. These advances hold great promise for improving cancer patient management and outcomes.

5. Clinical Translation and Challenges

Despite promising outcomes observed in preclinical studies, the clinical translation of nanodiagnostics faces several significant challenges that impede their widespread adoption in routine healthcare. One of the foremost concerns is the biocompatibility and long-term toxicity of nanoparticles[44]. Although many nanoparticle formulations show minimal acute toxicity, the potential for chronic accumulation and unforeseen effects in human tissues remains largely unknown. This uncertainty poses a barrier to gaining full clinical acceptance. Additionally, regulatory approval processes for nanodiagnostic agents are often prolonged and complex. The intricate manufacturing methods and multifaceted safety considerations related to nanoparticles contribute to delays in approval by regulatory bodies[44]. Moreover, there is currently no universally accepted standard for synthesizing, characterizing, and functionalizing nanoparticles, which makes reproducibility and quality control challenging. The lack of standardized protocols complicates the comparison of results across studies and the validation of diagnostic tools[44]. Furthermore, the high cost of production and difficulties in scaling up nanoparticle synthesis for commercial manufacturing limit the feasibility of broad clinical implementation.

Despite these hurdles, some nanoparticle-based diagnostics have successfully moved into clinical trials or even gained regulatory approval. For example, Ferumoxytol, an iron oxide nanoparticle initially approved for anemia treatment, has found off-label application as a magnetic resonance imaging (MRI) contrast agent in oncology, demonstrating the translational potential of nanoparticle technology.

6. Future Directions and Perspectives

The future landscape of nanodiagnostics is poised to evolve with exciting advancements that integrate multiple functionalities into single platforms. One emerging area is the development of integrated diagnostics that combine biosensing, imaging, and therapeutic functions—collectively known as theranostics. This convergence allows simultaneous disease detection and targeted treatment, improving patient outcomes. Another promising direction involves liquid biopsy platforms, where nanoparticles are engineered to detect circulating tumor DNA, exosomes, or circulating tumor cells in blood samples. These minimally invasive tests offer the potential for early cancer detection and real-time monitoring of disease progression. Artificial intelligence (AI) also plays a crucial role in the future of nanodiagnostics by enabling sophisticated analysis of complex nanosensor and imaging data, thereby enhancing diagnostic accuracy and reducing human error. Alongside these technological advances, the development of portable, user-friendly point-of-care nanodiagnostic devices aims to make cancer screening more accessible, especially in resource-limited settings. Ongoing research is focused on improving the safety profiles of nanoparticles, optimizing surface functionalization to increase specificity, and reducing manufacturing costs to facilitate mass production. Achieving these goals will require collaborative partnerships among academia, industry stakeholders, and regulatory agencies to streamline the path from bench to bedside, accelerating the clinical adoption of nanodiagnostics.

CONCLUSION

Nanodiagnostics holds immense promise in revolutionizing early cancer detection through highly sensitive biosensors and advanced imaging platforms. By enabling non-invasive, real-time, and accurate identification of malignancies at the molecular level, nanotechnology can bridge the existing gaps in cancer diagnosis and pave the way for personalized medicine. Continued research, standardization, and regulatory engagement are imperative to harness the full potential of nanodiagnostics in clinical oncology.

REFERENCES

1. Abbas, Z., Rehman, S., Abbas, Z., Rehman, S.: An Overview of Cancer Treatment Modalities. In: Neoplasm. IntechOpen (2018)
2. Abolhassani, H., Eskandari, A., Saremi Poor, A., Zarrabi, A., Khodadadi, B., Karimifard, S., Sahrayi, H., Bourbour, M., Tavakkoli Yaraki, M.: Nanobiotechnological approaches for breast cancer Management: Drug delivery systems and 3D In-Vitro models. Coordination Chemistry Reviews. 508, 215754 (2024). https://doi.org/10.1016/j.ccr.2024.215754
3. Acquah, J., Bosson-Amedenu, S., Eyiah-Bediako, F., Buabeng, A., Ouerfelli, N.: Modelling incidence and mortality cancer parameters with respect to GLOBOCAN 2020Age standardized world estimates. Heliyon. 10, e36836 (2024). https://doi.org/10.1016/j.heliyon.2024.e36836
4. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discover Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
5. Alum, E.U., Uti, D.E., Ugwu, O.P.-C., Alum, B.N., Edeh, F.O., Ainebyoona, C.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov Onc. 16, 646 (2025). https://doi.org/10.1007/s12672-025-02352-2
6. Koo, M.M., Swann, R., McPhail, S., Abel, G.A., Elliss-Brookes, L., Rubin, G.P., Lyratzopoulos, G.: Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. Lancet Oncol. 21, 73–79 (2020). https://doi.org/10.1016/S1470-2045(19)30595-9
7. Read "Diagnosing and Treating Adult Cancers and Associated Impairments" at NAP.edu.
8. Connal, S., Cameron, J.M., Sala, A., Brennan, P.M., Palmer, D.S., Palmer, J.D., Perlow, H., Baker, M.J.: Liquid biopsies: the future of cancer early detection. J Transl Med. 21, 118 (2023). https://doi.org/10.1186/s12967-023-03960-8
9. Alum, E.U.: AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis. Discov Onc. 16, 313 (2025). https://doi.org/10.1007/s12672-025-02064-7
10. Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., Wei, J.: Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Ther. 9, 336 (2024). https://doi.org/10.1038/s41392-024-02021-w
11. Jin, C., Wang, K., Oppong-Gyebi, A., Hu, J.: Application of Nanotechnology in Cancer Diagnosis and Therapy - A Mini-Review. International Journal of Medical Sciences. 17, 2964 (2020). https://doi.org/10.7150/ijms.49801

12. Dessale, M., Mengistu, G., Mengist, H.M.: Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis. Int J Nanomedicine. 17, 3735–3749 (2022). https://doi.org/10.2147/IJN.S378074
13. Bamodu, O.A., Chung, C.-C., Pisanic, T.R.: Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine. J Liq Biopsy. 2, 100126 (2023). https://doi.org/10.1016/j.jlb.2023.100126
14. Adhit, K.K., Wanjari, A., Menon, S., K, S.: Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis and Monitoring in Medicine. Cureus. 15, e50176. https://doi.org/10.7759/cureus.50176
15. Khan, Y., Sadia, H., Ali Shah, S.Z., Khan, M.N., Shah, A.A., Ullah, N., Ullah, M.F., Bibi, H., Bafakeeh, O.T., Khedher, N.B., Eldin, S.M., Fadhl, B.M., Khan, M.I.: Classification, Synthetic, and Characterization Approaches to Nanoparticles, and Their Applications in Various Fields of Nanotechnology: A Review. Catalysts. 12, 1386 (2022). https://doi.org/10.3390/catal12111386
16. Bandyopadhyay, K., Singh, S., Chaturvadi, V.K., Singh, A.K., Verma, A.: Recent advances in NIR-II emitting nanomaterials: design and biomedical applications of lanthanide complexes and functionalized mesoporous silica nanoparticles (MSNs). J. Mater. Chem. B. (2025). https://doi.org/10.1039/D5TB00911A
17. SV, S., Augustine, D., Hosmani, J., Pagnoni, F., Reda, R., Testarelli, L., Patil, S.: Nanoparticle-based biomolecules in cancer diagnosis, therapy, drug delivery and prognosis. Front Dent Med. 5, 1482166 (2024). https://doi.org/10.3389/fdmed.2024.1482166
18. Ammar, M.M., Ali, R., Abd Elaziz, N.A., Habib, H., Abbas, F.M., Yassin, M.T., Maniah, K., Abdelaziz, R.: Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics. Discov Onc. 16, 1172 (2025). https://doi.org/10.1007/s12672-025-02664-3
19. Karnwal, A., Kumar Sachan, R.S., Devgon, I., Devgon, J., Pant, G., Panchpuri, M., Ahmad, A., Alshammari, M.B., Hossain, K., Kumar, G.: Gold Nanoparticles in Nanobiotechnology: From Synthesis to Biosensing Applications. ACS Omega. 9, 29966–29982 (2024). https://doi.org/10.1021/acsomega.3c10352
20. Bakhshpour-Yücel, M., Aljayyousi, N., Osman, B., Lortlar Ünlü, N., Denizli, A., Ünlü, M.S.: Nanomaterial-Based Sensing Systems to Detect Neuropharmaceutical Compounds and Neurotransmitters. Sensors. 25, 3256 (2025). https://doi.org/10.3390/s25113256
21. Gaviria-Arroyave, M.I., Cano, J.B., Peñuela, G.A.: Nanomaterial-based fluorescent biosensors for monitoring environmental pollutants: A critical review. Talanta Open. 2, 100006 (2020). https://doi.org/10.1016/j.talo.2020.100006
22. He, Y., Hu, C., Li, Z., Wu, C., Zeng, Y., Peng, C.: Multifunctional carbon nanomaterials for diagnostic applications in infectious diseases and tumors. Mater Today Bio. 14, 100231 (2022). https://doi.org/10.1016/j.mtbio.2022.100231
23. Mishra, R., Minocha, S., Goel, R., Gaur, P.K., Lata, K., Singh, R.: Bioconvergence: advancing biosensors with nanotechnology for real-time health monitoring. Bulletin of the National Research Centre. 49, 14 (2025). https://doi.org/10.1186/s42269-025-01308-4
24. Dhasmana, A., Santhanam, A., Dhasmana, K., Malik, S., Preetam, S.: Innovative smart biosensors for cancer theranostics: A new frontier in detection, diagnosis, and beyond. Cancer Treatment and Research Communications. 43, 100911 (2025). https://doi.org/10.1016/j.ctarc.2025.100911
25. Noreen, S., Ishaq, I., Saleem, M.H., Ali, B., Muhammad Ali, S., Iqbal, J.: Electrochemical biosensing in oncology: a review advancements and prospects for cancer diagnosis. Cancer Biol Ther. 26, 2475581. https://doi.org/10.1080/15384047.2025.2475581
26. Breaking barriers in cancer diagnosis: unveiling the 4Ms of biosensors. RSC Advances. 15, 8019–8052 (2025). https://doi.org/10.1039/d4ra08212e
27. Kulkarni, M.B., Ayachit, N.H., Aminabhavi, T.M.: Recent Advancements in Nanobiosensors: Current Trends, Challenges, Applications, and Future Scope. Biosensors (Basel). 12, 892 (2022). https://doi.org/10.3390/bios12100892
28. Kumar, S., Wang, Z., Zhang, W., Liu, X., Li, M., Li, G., Zhang, B., Singh, R.: Optically Active Nanomaterials and Its Biosensing Applications—A Review. Biosensors (Basel). 13, 85 (2023). https://doi.org/10.3390/bios13010085
29. Sytu, M.R.C., Hahm, J.-I.: Principles and Applications of ZnO Nanomaterials in Optical Biosensors and ZnO Nanomaterial-Enhanced Biodetection. Biosensors. 14, 480 (2024). https://doi.org/10.3390/bios14100480
30. Pohanka, M.: Piezoelectric Chemosensors and Biosensors in Medical Diagnostics. Biosensors (Basel). 15, 197 (2025). https://doi.org/10.3390/bios15030197
31. Alapan, Y., Icoz, K., Gurkan, U.A.: Micro- and nanodevices integrated with biomolecular probes. Biotechnol Adv. 33, 1727–1743 (2015). https://doi.org/10.1016/j.biotechadv.2015.09.001

32. Hemdan, M., Abuelhaded, K., Shaker, A.A.S., Ashour, M.M., Abdelaziz, M.M., Dahab, M.I., Nassar, Y.A., Sarguos, A.M.M., Zakaria, P.S., Fahmy, H.A., Abdel Mageed, S.S., Hamed, M.O.A., Mubarak, M.F., Taher, M.A., Gumaah, N.F., Ragab, A.H.: Recent advances in nano-enhanced biosensors: Innovations in design, applications in healthcare, environmental monitoring, and food safety, and emerging research challenges. Sensing and Bio-Sensing Research. 48, 100783 (2025). https://doi.org/10.1016/j.sbsr.2025.100783
33. Noah, N.M., Ndangili, P.M.: Current Trends of Nanobiosensors for Point-of-Care Diagnostics. J Anal Methods Chem. 2019, 2179718 (2019). https://doi.org/10.1155/2019/2179718
34. Li, Z., Guo, M., Zhong, W.: Multiplex Detection of Biomarkers Empowered by Nanomaterials. Precis Chem. 3, 297–318. https://doi.org/10.1021/prechem.4c00096
35. Kim, C., Kang, M.S., Raja, I.S., Joung, Y.K., Han, D.-W.: Advancements in nanobiosensor technologies for in-vitro diagnostics to point of care testing. Heliyon. 10, e40306 (2024). https://doi.org/10.1016/j.heliyon.2024.e40306
36. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. Journal of Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
37. Mhlanga, N., Mphuthi, N., Van der Walt, H., Nyembe, S., Mokhena, T., Sikhwivhilu, L.: Nanostructures and nanoparticles as medical diagnostic imaging contrast agents: A review. Materials Today Chemistry. 40, 102233 (2024). https://doi.org/10.1016/j.mtchem.2024.102233
38. Sim, S., Wong, N.K.: Nanotechnology and its use in imaging and drug delivery (Review). Biomed Rep. 14, 42 (2021). https://doi.org/10.3892/br.2021.1418
39. Estelrich, J., Sánchez-Martín, M.J., Busquets, M.A.: Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine. 10, 1727–1741 (2015). https://doi.org/10.2147/IJN.S76501
40. Wang, W., Shang, S., Wang, Y., Xu, B.: Utilization of nanomaterials in MRI contrast agents and their role in therapy guided by imaging. Front Bioeng Biotechnol. 12, 1484577 (2024). https://doi.org/10.3389/fbioe.2024.1484577
41. Wegner, K.D., Hildebrandt, N.: Near infrared quantum dots for biosensing and bioimaging. TrAC Trends in Analytical Chemistry. 180, 117922 (2024). https://doi.org/10.1016/j.trac.2024.117922
42. Pijeira, M.S.O., Viltres, H., Kozempel, J., Sakmár, M., Vlk, M., İlem-Özdemir, D., Ekinci, M., Srinivasan, S., Rajabzadeh, A.R., Ricci-Junior, E., Alencar, L.M.R., Al Qahtani, M., Santos-Oliveira, R.: Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology. EJNMMI Radiopharm Chem. 7, 8 (2022). https://doi.org/10.1186/s41181-022-00161-4
43. Jiang, Z., Zhang, M., Li, P., Wang, Y., Fu, Q.: Nanomaterial-based CT contrast agents and their applications in image-guided therapy. Theranostics. 13, 483–509 (2023). https://doi.org/10.7150/thno.79625
44. Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L.W., Chang, J., Williams, G., Knowles, J.C., Poma, A.: Nanotechnology in healthcare, and its safety and environmental risks. Journal of Nanobiotechnology. 22, 715 (2024). https://doi.org/10.1186/s12951-024-02901-x
45 Orji OU, Ibiam UA, Aja PM, Ugwu P, Uraku AJ, Aloke C, Obasi OD, Nwali BU. Evaluation of the phytochemical and nutritional profiles of Cnidoscolus aconitifolius leaf collected in Abakaliki South East Nigeria. World J Med Sci. 2016;13(3):213-217.
46. Enechi OC, Okpe CC, Ibe GN, Omeje KO, Ugwu Okechukwu PC. Effect of Buchholzia coriacea methanol extract on haematological indices and liver function parameters in *Plasmodium berghei*-infected mice. Glob Veterinaria. 2016;16(1):57-66.
47. Alum EU, Uti DE, Ugwu Okechukwu PC, Alum BN. Toward a cure–Advancing HIV/AIDS treatment modalities beyond antiretroviral therapy: A review. Med. 2024;103(27):e38768.
48. Obeagu EI, Bot YS, Obeagu GU, Alum EU, Ugwu Okechukwu PC. Anaemia and risk factors in lactating mothers: A concern in Africa. Int J Innov Appl Res. 2024;11(2):15-17.
49.Alum EU, Ibiam UA, Ugwuja EI, Aja PM, Igwenyi IO, Offor CE, Orji UO, Ezeani NN, Ugwu OP, Aloke C, Egwu CO. Antioxidant effect of Buchholzia coriacea ethanol leaf extract and fractions on Freund's adjuvant-induced arthritis in albino rats: A comparative study. 2022;59(1):31-45.
50. Offor CE, Ugwu Okechukwu PC, Alum EU. Determination of ascorbic acid contents of fruits and vegetables. Int J Pharm Med Sci. 2015;5:1-3..
51. Amusa MO, Adepoju AO, Ugwu Okechukwu PC, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AOS. Effect of ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin-induced diabetic Wistar albino rats. IAA J Biol Sci. 2024;10(1):109-117.
52. Enechi YS, Ugwu OC, Ugwu Okechukwu PC, Omeh K. Evaluation of the antinutrient levels of *Ceiba pentandra* leaves. IJRRPAS. 2013;3(3):394-400.

53. Ugwu Okechukwu PC, Nwodo OFC, Joshua EP, Odo CE, Ossai EC. Effect of ethanol leaf extract of *Moringa oleifera* on lipid profile of malaria-infected mice. Res J Pharm Biol Chem Sci. 2014;4(1):1324-1332.
54. Ugwu OPC, Alum EU, Uhama KC. Dual burden of diabetes mellitus and malaria: Exploring the role of phytochemicals and vitamins in disease management. Res Inven J Res Med Sci. 2024;3(2):38-49.
55. Alum EU, Ugwu Okechukwu PC, Aja PM, Obeagu EI, Inya JE, Onyeije AP, Agu E, Awuchi CG. Restorative effects of ethanolic leaf extract of *Datura stramonium* against methotrexate-induced hematological impairments. Cogent Food Agric. 2013;9(1):2258774.
56. Offor CE, Nwankwegu FC, Joshua EP, Ugwu Okechukwu PC. Acute toxicity investigation and anti-diarrhoeal effect of the chloroform-methanol extract of the leaves of *Persea americana*. Iran J Pharm Res. 2014;13(2):651-658. PMID: 25237361; PMCID: PMC4157041.
57. Afiukwa CA, Oko AO, Afiukwa JN, Ugwu Okechukwu PC, Ali FU, Ossai EC. Proximate and mineral element compositions of five edible wild grown mushroom species in Abakaliki, southeast Nigeria. Res J Pharm Biol Chem Sci. 2013;4:1056-1064.
58. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. Med. 2024;103(28):e38834.
59. Obeagu EI, Ugwu OPC, Alum EU. Poor glycaemic control among diabetic patients; A review on associated factors. Newport Int J Res Med Sci (NIJRMS). 2023;3(1):30-33.
60. Nwaka AC, Ikechi-Agba MC, Okechukwu PU, Igwenyi IO, Agbafor KN, Orji OU, Ezugwu AL. The effects of ethanol extracts of *Jatropha curcas* on some hematological parameters of chloroform intoxicated rats. Am-Eur J Sci Res. 2015;10(1):45-49.
61. Ezeani NN, Ibiam UA, Orji OU, Igwenyi IO, Aloke C, Alum E, Aja PM, Ugwu OP. Effects of aqueous and ethanol root extracts of *Olax subscopioidea* on inflammatory parameters in complete Freund's adjuvant-collagen type II induced arthritic albino rats. Pharmacogn J. 2019;11(1)

CITE AS: Bwambale Isaac (2025). Role of Nanodiagnostics in Early Cancer Detection: Advances in Biosensors and Imaging Technologies. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 145-152. https://doi.org/10.59298/IDOSR/JES/112.145152